PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26680867-9	2002	Among the telomerase subunits, hTERT and c-Myc were the first factors to change after AZT treatment, subsequently, followed by the changes of hTR, Mad1 and TEP.	Zidovudine	86-89	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	41-46	
22931421-8	2013	AZT down-regulated the pro-proliferative genes encoding AKT1, MYC, STAT1, MAPK8, MAPK9, CCL-3, Bcl-3, and cyclin D2; pro-angiogenenic genes encoding VEGF and IL8; and genes involved in cell adhesion (ICAM1 and FN1) and the NF-kappaB pathway.	Zidovudine	0-3	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	62-65	
16132531-9	2005	Of the telomerase subunits, telomerase reverse transcriptase (hTERT) and c-Myc were the first to show a reduction in activity after AZT treatment, followed by changes in hTER , Mad1 and hTEP-1.	Zidovudine	132-135	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	73-78	
16132531-10	2005	CONCLUSION: Cyclic treatment with AZT initially suppressed hTERT and c-Myc, followed by suppression of hTER, Mad1 and hTEP-1.	Zidovudine	34-37	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	69-74	
26680867-10	2002	CONCLUSION: The suppression of hTERT and c-Myc by AZT treatment was the initial genetic phenomenon, subsequently followed by the changes of hTR, Mad1 and TEP.	Zidovudine	50-53	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	41-46	
27633795-8	2016	Regarding extratelomeric activities, our results showed a decrease of 64, 38 and 25% in the transcription of c-Myc, Cyc-D1 and TERT, respectively (p<0.05) after AZT treatment.	Zidovudine	164-167	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	109-114